Biolife Publisher is committed to upholding the integrity of all its publications. It is necessary therefore to agree on the standards of ethical behaviour expected from all parties involved in the publishing process; these include the author, the editor, the peer reviewer and the\u00a0<\/strong>publisher<\/strong>.<\/p>\n Biolife Publisher follows the COPE Best Practice Guidelines on publishing ethics. Full details of these guidelines can be found on the COPE<\/a> website.<\/p>\n Biolife Publisher does not tolerate plagiarism, or the publication of material that is libellous, illegal or which infringes the copyright or other rights of any third party. In addition, the manipulation of scientific data, tables, figures or any text for the purpose of knowingly providing incorrect information in order to manipulate the process of peer review is strictly prohibited.<\/p>\n <\/p>\n Authorship<\/strong><\/p>\n Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.<\/p>\n The list of authors should include all those who can legitimately claim authorship. This is all those who:<\/p>\n Please follow our guidelines in “instructions for Authors”<\/a><\/p>\n Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the\u00a0International Committee of Medical Journal Editors (ICMJE) authorship guidelines<\/a>\u00a0for more information on authorship.<\/p>\n Authors publishing a paper with Biolife Publisher should certify that:<\/strong><\/p>\n Above all, authors should be transparent.\u00a0 For example, if an author is not sure whether her paper is original (for instance, whether it might constitute duplicate publication), she should inform the journal’s editor. If the editor decides it is appropriate to publish, the paper itself should state clearly any potential overlap.<\/p>\n <\/p>\n Writing assistance<\/strong><\/p>\n Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company, and level of input – and identify the entity that paid for this assistance.<\/p>\n It is not necessary to disclose the use of language polishing services.<\/p>\n Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.<\/p>\n <\/p>\n Declaration of conflicting interests<\/strong><\/p>\n European Journal of Neurodegenerative Diseases<\/em> requires a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.<\/p>\n Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.<\/p>\n For guidance on conflict of interest statements, please see the\u00a0ICMJE recommendations for the Disclosure of Financial and Non-Financial Relationships and Activities, and Conflicts of Interest<\/a>.<\/p>\n <\/p>\n Funding<\/strong><\/p>\n European Journal of Neurodegenerative Diseases<\/em> requires all authors to acknowledge their funding in a consistent fashion under a separate heading.<\/p>\n <\/p>\n Inclusion and Confidentiality<\/strong><\/p>\n The Editor or peer reviewer of any Biolife Publisher publication shall evaluate manuscripts on their intellectual content, irrespective of the race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors. The Editor and any editorial staff shall not disclose any confidential information concerning a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, or publisher, as appropriate. The content of any unpublished materials disclosed in a submitted manuscript is not to be used, either in whole or in part, in an editor’s own research without the express written consent of the submitting author.<\/p>\n <\/p>\n Plagiarism Policy and Data Integrity<\/strong><\/p>\n EJND<\/em> has a zero tolerance policy for plagiarism. The journal rejects all forms of plagiarism, data fabrication, and falsification. During screenings, submissions must show an overall text similarity score below 15% and under 3% from any single outside source. Authors must clearly cite and limit reuse from their own prior work to avoid self-plagiarism.<\/p>\n <\/p>\n Data Integrity and Verification<\/strong><\/p>\n During evaluation, Reviewers or editors may request access to raw data, including original, unedited data files, clinical trial logs, or lab notes.<\/p>\n Image Standards: Authors must not enhance, crop out, or manipulate blots, gels, or microscopy images in a way that misleads the reader.<\/p>\n Statistical Rigor: The methods section must fully explain all software, algorithms, and statistical tests used to analyze patient cohorts or cellular models.<\/p>\n The journal publishes formal errata for honest errors or complete retractions for compromised data following COPE<\/a> guidelines.<\/p>\n <\/p>\n Misconduct<\/strong><\/p>\n The publisher, Biolife Publisher, affirms that any misconduct, in the form of fabrication, falsification or plagiarism, jeopardizes the success of the entire scientific endeavor. Any questions raised with regard to possible misconduct or plagiarism will initially be evaluated by the editor(s) of the publication, in consultation with the manuscript’s peer reviewer(s) if appropriate. If deemed appropriate, the matter will be taken up with the institution where the scientific work in question was performed. In principle, matters will be reviewed in accordance with the institutional procedures for handling allegations of misconduct. At all stages, every effort should be made to ensure that the process is fair and just, both for those who have been accused of misconduct and for those who have raised the issue of scientific misconduct. In the event that a published article must be retracted or corrected, a statement of retraction or correction, usually in the form of an erratum, will be published. Articles may be removed from the publication if deemed appropriate.<\/p>\n <\/p>\n Biolife Publisher expects authors to abide by the general ethics polices outlined by The Council of Science Editors (CSE) and COPE. Please use the links below as references.<\/p>\n Science Editor-Publications released by the Council of Science Editors<\/a><\/p>\n COPE-General approach to publication ethics for the editorial office<\/a><\/p>\n\n
\nWhen a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.\n\n